

## **i3 in India**

# Comprehensive drug development resources for faster results

Biopharmaceutical companies increasingly identify India as a strategic study location due to its substantial patient supply and ability to deliver a rapid return on investment. Today, India offers virtually any clinical development programme benefits that include:

- Large pools of prospective patients that can be rapidly accessed
- High patient retention rates
- Quick trial timelines
- Swift regulatory approval

To help sponsors capitalise on these benefits without sacrificing quality, i3 has established a significant presence throughout India that includes:

- An extensive network of investigators and sites
- A full complement of data management experts
- A rapidly expanding pharmacovigilance team
- Complete functional service provision (FSP) capabilities

Call on us to help you access the nation's large patient populations for all types of therapeutic indications, and obtain robust data that meets the industry's most exacting standards—at favourable costs, and on a more advantageous timetable.

### **Research in India: Part of a smart global strategy**

The gap between prevalence and treatment rates remains high for the Indian population in a range of diseases spanning anti-infective, gastrointestinal, respiratory, and pain management therapies. The resulting availability of drug-naïve patients, combined with the vast patient pool available across almost all the major therapeutic areas, allows for faster recruitment of patients in India compared to many other countries.

Partnering with i3 in India can help you advance your research in key indications, including:

- Infectious disease, notably HIV/AIDS
- Cardiology

### **Advantage: India**

India ranks favorably in these key factors for clinical research:

- Number of patients across urban lifestyle disease
- Number of patients across tropical diseases
- Site and patient recruitment speed
- Trial completion speed
- Patient return rate
- Adherence to quality and regulatory standards
- Scope and quality of data management services



- Endocrinology and metabolic disease
- Oncology
- Central nervous system

Retention rates for patients participating in clinical trials in India are also higher than in many other regions, including North America.

### **A strong base of operations with local talent and local knowledge**

i3 is strongly positioned to enhance access to pools of patients through its connections with investigators

throughout the region. We maintain an extensive database of more than 500 sites located in both large government hospitals and private hospitals throughout India, and have on-site experience with many leading investigators who have taken initiatives to set up clinical research units within their own hospitals.

Our regulatory services in India are also well established. i3 has a solid track record in ICH-GCP compliance and quality that includes ample experience with the submission of requirements at the Ministry of Health level as well as at the site level. We are also accomplished at minimising cultural differences and difficulties on engagements of any size or scope.

i3 in India also offers:

- Experience from 24 global studies at more than 200 sites
- Dedicated clinical monitoring and project management teams
- Well-equipped, safe, modern, and comfortable working environments
- A comprehensive, state-of-the-art IT infrastructure featuring:
  - High-speed telecommunications capabilities
  - Leading technology support services, including provisioning and desk-side/end-user support

### **Dedicated data management and drug safety expertise**

In addition to offering a full complement of data management services—with solutions that include data capture, summary, analysis, and reporting for clinical trials across all phases of research—i3 in India can provide deep expertise in all aspects of drug safety and epidemiology. In fact, we are currently adding nearly a score of pharmacovigilance staff at our Pune location, including a drug safety physician who holds an MD licence in India, as we continue to expand our adverse event case processing and medical review services.

### **Functional outsourcing and strategic staffing transfers**

India's unique advantages as a location for drug development led us to make it the "offshore" hub of our centralised functional service provision (FSP) capabilities. Tailored to meet specific, urgent needs, i3's freestanding FSP teams can support sponsors in their core competencies by handling transactional workloads, often serving as the equivalent of an entire department.

We can also provide staff transitions to reduce headcounts in accordance with local legal requirements, allowing you to transfer your own internal employees to i3 for re-engagement as an FSP team already familiar with your system and culture.

Find out how i3's specialised approach and proven local resources throughout India can support your next project.

### **Contact us**

[specialists@i3global.com](mailto:specialists@i3global.com)

[www.i3global.com](http://www.i3global.com)

---

### **About i3**

i3's full-spectrum functional and therapeutic expertise helps pharmaceutical companies gain sharper insights that lead to better patient care. Faster and more efficiently. With less risk and expense. For solutions that combine consulting-firm flexibility with the scientific depth of an integrated research organisation, look to the specialists of i3.

Clinical Research  
Data Services  
Pharmacovigilance  
Staffing and Outsourcing

Cardiology  
Central Nervous System  
Oncology  
Respiratory & Infectious Disease  
Endocrinology & Metabolic Disease